Benefits of locally delivered antibiotics is supported by strong scientific evidence.

Gelcide offers you an effective way to combat biofilm and bacterial infections by:

- Complementing your mechanical debridement in the deep periodontal pockets.
- Ensuring wound healing in satitudes, and
- Limiting the risk of infection in post-extraction areas.

References

1. Jacob, S. Global Prevalence of Periodontitis: a literature review, sjad.org

Securing patient compliance

Only 60% of patients complete treatments that use systemic antibiotics.

Offering patients more choices

A modern medical approach that improves retention rates and attracts new patients because of reduction in patient stress and better treatment outcomes.

Safe attainment of MIC levels

Use of local treatment in the affected area means patient’s body avoids any risks of reaching toxic antibiotic levels.

Locally administered treatments

Gelcide is administered at site of infection, resulting in higher success rates than use of solely systemic antibiotics.

No side effects

Side effects eliminated because of local application at site of infection.

Contact Us

If you have any questions do not hesitate to contact us or our local partners.

Blegistrasse 11B
6341 Baar
Switzerland
+41 (0)61 225 60 68 / 69
info@medtechdental.com
www.medtechdental.com

Increasing the Effectiveness of Periodontal Pockets Treatment

One of the most widespread pathologies globally.

Periodontitis affects 50–60% of the adult population worldwide. This chronic infectious condition has been linked to other serious illnesses, such as diabetes and heart disease.

As this is a chronic disease, patients can get frustrated with the time and financial effort needed in the process of dealing with it. This can often lead to patients leaving practices in order to find treatment elsewhere.

Since the 1960s, scaling and root planning (SRP) has proven its success as the first non-surgical method for treating periodontitis. However, it has certain limitations – in particular in its weakness in reaching deeper pockets. Clinical studies have shown that reinforcing SRP with antibiotic medication can improve treatment outcomes significantly as this helps combat mechanically unreachable areas.

Up to now systemic antibiotics have been the norm, as today 7 to 11% of antibiotics consumed are prescribed by dentists.

Yet recent studies have shown that systemic antibiotics may have side effects as well as increased risk of causing bacterial resistance.

SRP effectiveness as a stand-alone treatment according to pocket site

Because dental-bone preservation is at the heart of every smile.

Gelcide solves the problems posed by systemic antibiotics by offering complete on-site treatment, eliminating side effects and not contributing to an increase in bacterial resistance.
What is Gelcide? What differentiates Gelcide from other treatments?

Gelcide consists of a patented solution of piperacillin and tazobactam paired with a carrier that effectively dispenses the potent active formula right to the bottom of the dental pocket or the wound. The local-delivery application minimizes some of the problems of systemic antibiotics, such as side effects and increased bacterial resistance.

Because it is applied directly as a liquid to the affected area, Gelcide is particularly suitable for preventing damage to the surrounding bone. Its unique formula allows it to rapidly penetrate into the pocket and subsequently gelify inside, while, on the surface, it creates a strong external film that virtually seals the wound. These capabilities allow for easy application while ensuring that the active ingredients are retained at the infection site.

Current SRP treatments are rendered less effective because of poor patient compliance. They place the burden of treatment on patients themselves, expecting them to self-administer antibiotics up three times a day off site. Gelcide allows the practitioner full control of the treatment process, and as a result increases the certainty of treatment outcomes.

Gelcide’s exclusive formula is slowly released at effective concentrations for up to 8–10 days. The film is permeable but insoluble to fluids – protecting the pocket from further oral-bacteria exposure, subsequent irritation and infection.

This patented solution offers you an effective way of complementing standard SRP treatment. It will improve success rates, help prevent early body reabsorption and potential displacements – resulting in increased therapy compliance and more satisfied patients.

Improved Effectiveness over Time

• Highly effective against a broad range of gram+ and gram- bacteria through antibiotic activity of piperacillin. Beta lactamase-induced bacterial resistance is prevented through coadministration of tazobactam.
• Biodegradable and anti-microbial active for 7–10 days.
• Once opened, remains active for 4 weeks.

Treatment and Practice Benefits

• Increased treatment compliance as doctor has higher control of the therapy.
• Dentist builds trust and loyalty by offering most up-to-date treatments that mean far less intrusion in patient’s day-to-day life.
• Incremental revenue with low incremental workload.

Patient Benefits

• No side effects due to 100-fold higher levels of concentration of active agent in subgingival site compared to systemic therapy.
• Slow-release mechanism and complete on-site treatment eliminate need for patients to follow up treatment off site.
• Unique film means patients do not need to adapt eating or drinking habits throughout duration of treatment.

Why Gelcide?

Ease of Application

• Fluid mix that penetrates deep into the dental pocket.
• Once applied, Gelcide ‘seals’ the pocket, solidifying as a gel after contact with fluids, thereby remaining in the pocket and acting as a film when making contact with air at the gingival level.
• No need for additional injection devices: all elements are included.
• No need to worry about patient compliance: all work can be carried out on site.

Improved Effectiveness over Time

• Highly effective against a broad range of gram+ and gram- bacteria through antibiotic activity of piperacillin. Beta lactamase-induced bacterial resistance is prevented through coadministration of tazobactam.
• Biodegradable and anti-microbial active for 7–10 days.
• Once opened, remains active for 4 weeks.

Key Attributes

- Not absorbed by the gastro-intestinal tract.
- No residuals: water permeable.
- Non-irritant and causes no discomfort.
- All application on site.